A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome

H. Nashat (London, United Kingdom), C. Harries (London, United Kingdom), L. Parfitt (London, United Kingdom), E. Shaw (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom)

Source: International Congress 2018 – Pulmonary hypertension: therapy

Session: Pulmonary hypertension: therapy
Session type: Thematic Poster
Number: 3046

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Nashat (London, United Kingdom), C. Harries (London, United Kingdom), L. Parfitt (London, United Kingdom), E. Shaw (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), M. Gatzoulis (London, United Kingdom), K. Dimopoulos (London, United Kingdom), S. Wort (London, United Kingdom). A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome. 3046

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.